Ocular Therapeutix (OCUL) has been drawing fresh attention after recent trading moves, with the stock closing at US$9.01 and posting mixed short term returns across the past week, month and past 3 months.

Recent trading puts that US$9.01 share price in context, with short term share price momentum firming over the past week but still weaker year to date, while longer term total shareholder returns over one and three years remain positive.

If you are watching Ocular Therapeutix and want more biotech ideas linked to similar themes in eye care and treatment, take a look at 37 healthcare AI stocks

With Ocular Therapeutix posting strong recent revenue and net income growth yet still trading well below the average analyst price target and an internal value estimate, the key question is whether this gap signals opportunity or if the market is already incorporating expectations for future growth into the share price.

Most Popular Narrative: 65.3% Undervalued

At a last close of $9.01 versus a widely followed fair value of $26, the leading narrative frames Ocular Therapeutix as heavily discounted while hinging that view on ambitious growth and profitability assumptions.

The anticipated approval of AXPAXLI, potentially the first wet AMD product with a superiority label and longer dosing intervals (every 6–12 months), may allow Ocular Therapeutix to capture significant market share in a rapidly growing population of elderly patients with retinal disease, unlocking large revenue growth opportunities as the global prevalence of ophthalmic disorders increases.

Want to see what revenue curve, margin swing, and future earnings multiple are baked into that $26 figure? The narrative leans on aggressive top line growth, a sharp turn in profitability, and a rich earnings multiple more often associated with mature leaders than loss making biotechs.

Result: Fair Value of $26 (UNDERVALUED)

However, the story could change quickly if AXPAXLI stumbles in SOL-1 or SOL-R, or if payer pushback limits pricing power and slows adoption.

Another Angle: Rich Sales Multiple vs “Cheap” Fair Value

The SWS DCF model points to a fair value of $92.45, which presents OCUL as very undervalued at $9.01. Yet on a sales basis the stock trades on a P/S of 37.9x compared with 6.4x for the US Pharmaceuticals industry, 5.4x for peers and a fair ratio of just 0.1x, which means a lot has to go right for today’s price to look conservative.

Next Steps

The bullish and cautious threads in this story sit side by side, so check the numbers yourself, weigh the trade offs, and see the full picture with 2 key rewards and 2 important warning signs

Looking for more investment ideas?

If Ocular Therapeutix is on your radar, do not stop there. Use curated lists to spot other opportunities before they end up on everyone else's watchlist.

• Target potential mispriced opportunities by scanning 46 high quality undervalued stocks that combine stronger fundamentals with more attractive pricing.
• Prioritise resilience by filtering for 62 resilient stocks with low risk scores that score well on balance sheet strength and risk checks.
• Hunt for underfollowed opportunities through a screener containing 22 high quality undiscovered gems that many investors may not be watching yet.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.